Defining cancer risk in dermatomyositis. Part I
Summary The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion‐body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle‐specific en...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental dermatology 2009-06, Vol.34 (4), p.451-455 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 455 |
|---|---|
| container_issue | 4 |
| container_start_page | 451 |
| container_title | Clinical and experimental dermatology |
| container_volume | 34 |
| creator | Madan, V. Chinoy, H. Griffiths, C. E. M. Cooper, R. G. |
| description | Summary
The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion‐body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle‐specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two‐part review series, we examine the evidence for the existence of cancer‐associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM. |
| doi_str_mv | 10.1111/j.1365-2230.2009.03216.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67371852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67371852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5016-3c384ea563713e66ba63ff743f3d190c24968f5786ab569f5988a07d6a105aa13</originalsourceid><addsrcrecordid>eNqNkMlOwzAQhi0EoqXwCigXuCX12LFjHzigtixSxSaWo-WmNnLJAnYq2rcnoVW54stY8vfPeD6EIsAJtGe4SIByFhNCcUIwlgmmBHiy2kP93cM-6mOKs5hLKnroKIQFxkAhY4eoB5IRIgX00XBsrKtc9R7lusqNj7wLH5GrornxpW7qcl0H17iQRA_aN9HtMTqwugjmZFsH6OVq8jy6iaf317ejy2mcMww8pjkVqdGM0wyo4XymObU2S6mlc5A4J6nkwrJMcD1jXFomhdA4m3MNmGkNdIDON30_ff21NKFRpQu5KQpdmXoZFM_azoKRFhQbMPd1CN5Y9eldqf1aAVadLLVQnRPVOVGdLPUrS63a6Ol2xnJWmvlfcGunBc62gA65LqxvFbmw4wikEmSGW-5iw327wqz__QE1moy7W5uPN3kXGrPa5bX_-N2Tqbe7a0XfODyy9FU90R80dpE9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67371852</pqid></control><display><type>article</type><title>Defining cancer risk in dermatomyositis. Part I</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Madan, V. ; Chinoy, H. ; Griffiths, C. E. M. ; Cooper, R. G.</creator><creatorcontrib>Madan, V. ; Chinoy, H. ; Griffiths, C. E. M. ; Cooper, R. G.</creatorcontrib><description>Summary
The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion‐body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle‐specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two‐part review series, we examine the evidence for the existence of cancer‐associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1111/j.1365-2230.2009.03216.x</identifier><identifier>PMID: 19522981</identifier><identifier>CODEN: CEDEDE</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Biological and medical sciences ; Dermatology ; Dermatomyositis - complications ; Dermatomyositis - diagnosis ; Dermatomyositis - epidemiology ; Evidence-Based Medicine ; Female ; Humans ; Male ; Medical sciences ; Neoplasms - complications ; Neoplasms - epidemiology ; Polymyositis - complications ; Polymyositis - epidemiology ; Risk Factors ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><ispartof>Clinical and experimental dermatology, 2009-06, Vol.34 (4), p.451-455</ispartof><rights>2009 The Author(s). Journal compilation © 2009 British Association of Dermatologists</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5016-3c384ea563713e66ba63ff743f3d190c24968f5786ab569f5988a07d6a105aa13</citedby><cites>FETCH-LOGICAL-c5016-3c384ea563713e66ba63ff743f3d190c24968f5786ab569f5988a07d6a105aa13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21491970$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19522981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Madan, V.</creatorcontrib><creatorcontrib>Chinoy, H.</creatorcontrib><creatorcontrib>Griffiths, C. E. M.</creatorcontrib><creatorcontrib>Cooper, R. G.</creatorcontrib><title>Defining cancer risk in dermatomyositis. Part I</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>Summary
The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion‐body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle‐specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two‐part review series, we examine the evidence for the existence of cancer‐associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM.</description><subject>Biological and medical sciences</subject><subject>Dermatology</subject><subject>Dermatomyositis - complications</subject><subject>Dermatomyositis - diagnosis</subject><subject>Dermatomyositis - epidemiology</subject><subject>Evidence-Based Medicine</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - epidemiology</subject><subject>Polymyositis - complications</subject><subject>Polymyositis - epidemiology</subject><subject>Risk Factors</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMlOwzAQhi0EoqXwCigXuCX12LFjHzigtixSxSaWo-WmNnLJAnYq2rcnoVW54stY8vfPeD6EIsAJtGe4SIByFhNCcUIwlgmmBHiy2kP93cM-6mOKs5hLKnroKIQFxkAhY4eoB5IRIgX00XBsrKtc9R7lusqNj7wLH5GrornxpW7qcl0H17iQRA_aN9HtMTqwugjmZFsH6OVq8jy6iaf317ejy2mcMww8pjkVqdGM0wyo4XymObU2S6mlc5A4J6nkwrJMcD1jXFomhdA4m3MNmGkNdIDON30_ff21NKFRpQu5KQpdmXoZFM_azoKRFhQbMPd1CN5Y9eldqf1aAVadLLVQnRPVOVGdLPUrS63a6Ol2xnJWmvlfcGunBc62gA65LqxvFbmw4wikEmSGW-5iw327wqz__QE1moy7W5uPN3kXGrPa5bX_-N2Tqbe7a0XfODyy9FU90R80dpE9</recordid><startdate>200906</startdate><enddate>200906</enddate><creator>Madan, V.</creator><creator>Chinoy, H.</creator><creator>Griffiths, C. E. M.</creator><creator>Cooper, R. G.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200906</creationdate><title>Defining cancer risk in dermatomyositis. Part I</title><author>Madan, V. ; Chinoy, H. ; Griffiths, C. E. M. ; Cooper, R. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5016-3c384ea563713e66ba63ff743f3d190c24968f5786ab569f5988a07d6a105aa13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>Dermatology</topic><topic>Dermatomyositis - complications</topic><topic>Dermatomyositis - diagnosis</topic><topic>Dermatomyositis - epidemiology</topic><topic>Evidence-Based Medicine</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - epidemiology</topic><topic>Polymyositis - complications</topic><topic>Polymyositis - epidemiology</topic><topic>Risk Factors</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Madan, V.</creatorcontrib><creatorcontrib>Chinoy, H.</creatorcontrib><creatorcontrib>Griffiths, C. E. M.</creatorcontrib><creatorcontrib>Cooper, R. G.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Madan, V.</au><au>Chinoy, H.</au><au>Griffiths, C. E. M.</au><au>Cooper, R. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Defining cancer risk in dermatomyositis. Part I</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2009-06</date><risdate>2009</risdate><volume>34</volume><issue>4</issue><spage>451</spage><epage>455</epage><pages>451-455</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><coden>CEDEDE</coden><abstract>Summary
The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion‐body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle‐specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two‐part review series, we examine the evidence for the existence of cancer‐associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19522981</pmid><doi>10.1111/j.1365-2230.2009.03216.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 2009-06, Vol.34 (4), p.451-455 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67371852 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Biological and medical sciences Dermatology Dermatomyositis - complications Dermatomyositis - diagnosis Dermatomyositis - epidemiology Evidence-Based Medicine Female Humans Male Medical sciences Neoplasms - complications Neoplasms - epidemiology Polymyositis - complications Polymyositis - epidemiology Risk Factors Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis |
| title | Defining cancer risk in dermatomyositis. Part I |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T07%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Defining%20cancer%20risk%20in%20dermatomyositis.%20Part%20I&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Madan,%20V.&rft.date=2009-06&rft.volume=34&rft.issue=4&rft.spage=451&rft.epage=455&rft.pages=451-455&rft.issn=0307-6938&rft.eissn=1365-2230&rft.coden=CEDEDE&rft_id=info:doi/10.1111/j.1365-2230.2009.03216.x&rft_dat=%3Cproquest_cross%3E67371852%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67371852&rft_id=info:pmid/19522981&rfr_iscdi=true |